Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer

IF 0.1 Q4 ONCOLOGY
D. Mikhaylenko, S. A. Sergienko, B. Alekseev, A. Kaprin, M. Nemtsova
{"title":"Basic characteristics and features of the molecular genetic test systems designed for non-invasive diagnostics and prognosis of prostate cancer and bladder cancer","authors":"D. Mikhaylenko, S. A. Sergienko, B. Alekseev, A. Kaprin, M. Nemtsova","doi":"10.17650/1726-9776-2019-15-4-18-29","DOIUrl":null,"url":null,"abstract":"Improving the laboratory diagnosis of prostate cancer and bladder cancer are still an actual problem in modern urologic oncology. Test systems for DNA or RNA alterations that occurred during carcinogenesis and associated with the malignant tumor and the prognosis of disease have been actively developed in recent years. Here we reviewed the data published mainly in the last 5 years about the molecular genetic kits for diagnosis (Progensa, SelectMDx, ExoDx Prostate Test, Prosta-Test, Confirm MDx) and assessment of prognosis (Prolaris, Decipher, Oncotype DX) in patients with prostate cancer, discussed their sensitivity and specificity. The characteristics of analogous kits and panels for bladder cancer (UroVysion, CertNDx Bladder Cancer Assay, UroSEEK, mutations in the FGFR3 and TERT genes, and the Cxbladder Monitor/Detect/Triage kit's line) were systematized. Particularly we focused on the description of the patient cohorts for whom kits mentioned above have greater diagnostic accuracy, described limitations of these test systems in consequence both a methodological and registration aspects, and their use in combination with other tumor markers. This review is aimed at oncologists, urologists, laboratory geneticists and specialists in related professions.","PeriodicalId":42924,"journal":{"name":"Onkourologiya","volume":"1 1","pages":""},"PeriodicalIF":0.1000,"publicationDate":"2020-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Onkourologiya","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17650/1726-9776-2019-15-4-18-29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Improving the laboratory diagnosis of prostate cancer and bladder cancer are still an actual problem in modern urologic oncology. Test systems for DNA or RNA alterations that occurred during carcinogenesis and associated with the malignant tumor and the prognosis of disease have been actively developed in recent years. Here we reviewed the data published mainly in the last 5 years about the molecular genetic kits for diagnosis (Progensa, SelectMDx, ExoDx Prostate Test, Prosta-Test, Confirm MDx) and assessment of prognosis (Prolaris, Decipher, Oncotype DX) in patients with prostate cancer, discussed their sensitivity and specificity. The characteristics of analogous kits and panels for bladder cancer (UroVysion, CertNDx Bladder Cancer Assay, UroSEEK, mutations in the FGFR3 and TERT genes, and the Cxbladder Monitor/Detect/Triage kit's line) were systematized. Particularly we focused on the description of the patient cohorts for whom kits mentioned above have greater diagnostic accuracy, described limitations of these test systems in consequence both a methodological and registration aspects, and their use in combination with other tumor markers. This review is aimed at oncologists, urologists, laboratory geneticists and specialists in related professions.
用于前列腺癌和膀胱癌无创诊断和预后的分子基因检测系统的基本特征和特点
提高前列腺癌和膀胱癌的实验室诊断水平仍是现代泌尿肿瘤学面临的现实问题。近年来,肿瘤发生过程中与恶性肿瘤和疾病预后相关的DNA或RNA改变的检测系统得到了积极的发展。本文回顾了近5年来发表的用于前列腺癌患者诊断的分子基因试剂盒(Progensa、SelectMDx、ExoDx前列腺测试、prota -Test、Confirm MDx)和预后评估的分子基因试剂盒(Prolaris、Decipher、Oncotype DX)的敏感性和特异性。对膀胱癌类似试剂盒和检测板(UroVysion、CertNDx膀胱癌检测、UroSEEK、FGFR3和TERT基因突变以及cx膀胱监测/检测/分诊试剂盒系列)的特点进行了系统化分析。我们特别关注了对上述试剂盒具有更高诊断准确性的患者群体的描述,描述了这些测试系统在方法学和注册方面的局限性,以及它们与其他肿瘤标志物的结合使用。本综述针对肿瘤学家、泌尿科医生、实验室遗传学家和相关专业的专家。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Onkourologiya
Onkourologiya ONCOLOGY-
CiteScore
0.40
自引率
0.00%
发文量
59
审稿时长
10 weeks
期刊介绍: The main objective of the journal "Cancer urology" is publishing up-to-date information about scientific clinical researches, diagnostics, treatment of oncologic urological diseases. The aim of the edition is to inform the experts on oncologic urology about achievements in this area, to build understanding of the necessary integrated interdisciplinary approach in therapy, alongside with urologists, combining efforts of doctors of various specialties (cardiologists, pediatricians, chemotherapeutists et al.), to contribute to raising the effectiveness of oncologic patients’ treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信